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ABSTRACT Botulism is caused by botulinum neurotoxin (BoNT), the most poison-
ous substance known. BoNTs are also classified as tier 1 biothreat agents due to
their high potency and lethality. The existence of seven BoNT serotypes (A to G),
which differ by 35% to 68% in amino acid sequences, necessitates the development
of serotype-specific countermeasures. We present results of a phase 1 clinical study
of an anti-toxin to BoNT serotypes C and D, NTM-1634, which consists of an
equimolar mixture of four fully human IgG1 monoclonal antibodies (MAbs), each
binding to nonoverlapping epitopes on BoNT serotypes C and D, resulting in potent
toxin neutralization in rodents. This first in-human study evaluated the safety and
pharmacokinetics of escalating doses of NTM-1634 administered intravenously to
healthy adults. Three cohorts of eight healthy subjects received single intravenous
doses of NTM-1634 at 0.33 mg/kg, 0.66 mg/kg, or 1 mg/kg or placebo. Follow-up ex-
aminations and pharmacokinetics evaluations were continued up to 121 days postin-
fusion. Subjects were monitored by using physical examinations, hematology and
chemistry blood tests, and electrocardiograms. Pharmacokinetics parameters were
estimated using noncompartmental methods. The results demonstrated that the ma-
terials were safe and well tolerated with the expected half-lives for human MAbs
and with minimal antidrug antibodies detected over the dose ranges and duration
of the study. (This study has been registered at ClinicalTrials.gov under identifier
NCT03046550.)
KEYWORDS botulinum neurotoxin, safety, pharmacokinetics, monoclonal antibody,
antibody combinations, phase 1 clinical trial, antitoxin, oligoclonal antibodies,
recombinant antibodies
Botulism, an acute life-threatening flaccid paralysis affecting both humans andanimals, is caused by botulinum neurotoxins (BoNTs) produced by the bacterium
Clostridium botulinum and additional Clostridia species (1, 2). Naturally occurring bot-
ulism is an orphan disease, with approximately 120 cases/year in the United States.
BoNTs are also classified as tier 1 biothreat agents, the highest level of classification,
due to their high potency and lethality (3). As such, the U.S. government has funded the
development of botulinum antitoxins, including those reported here.
Of the seven immunologically distinct types of BoNTs (A to G) (4–6), serotypes A, B,
E, and F cause most of the naturally occurring human disease, including foodborne,
wound, and intestinal botulism. Sequence analysis of BoNT/C and BoNT/D strains
reveals the existence of mosaic toxins that contain portions of both BoNT/C and
BoNT/D as well as sequences unique to the mosaics (7, 8). BoNT C/D has the sequence
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of BoNT/C for the amino-terminal two-thirds of the toxin but is 95% identical to the
sequence of BoNT/D for the carboxy-terminal one-third. BoNT D/C has high identity
with the BoNT/D amino terminus but shares a lower identity with the BoNT/C and
BoNT/D carboxy termini (8). BoNT/C and BoNT/D most frequently intoxicate nonhu-
mans, with BoNT/C and C/D causing botulism in avian species (9, 10) as well as feline
and canine species; BoNT/D and D/C most frequently cause botulism in cattle (11, 12).
BoNT/C and BoNT/D, however, can also cause botulism in humans (13). Two cases of
foodborne botulism and one case of infant botulism have been attributed to BoNT/C
(14). BoNT/D organisms have also been found in tainted ham that caused botulism in
several individuals (15). BoNT/C blocks neuromuscular transmission in human neuro-
muscular junction preparations and causes prolonged inhibition of exocytosis in cer-
ebellar granular neurons. Both BoNT/C and BoNT D/C cause lethal botulism in nonhu-
man primates exposed via the aerosol route. Finally, BoNT C/D is therapeutically active
in treating dystonia in humans (16). These studies indicate that BoNT/C and BoNT/D
and their mosaic toxins pose a similar biothreat as other BoNT serotypes. Thus, the
development of countermeasures for all seven serotypes is a high priority of the
National Institute for Allergy and Infectious Diseases (NIAID) and the Department of
Health and Human Services (17).
The only treatment for botulism is antitoxin. As a result, the Public Health Emer-
gency Medical Countermeasure Enterprise (PHEMCE) has a requirement for polyclonal
BoNT antitoxin for the national stockpile for intentional botulism (17). The current
treatment for adult botulism is heptavalent (serotypes A to G) equine botulism anti-
toxin (BAT) (18). BAT is immunogenic, and hypersensitivity reactions have been re-
ported, including serum sickness and asystole (18). BAT is an F(ab=)2 product with short
serum half-lives (7.5 to 34.2 h), which eliminates its use for prevention of botulism and
limits its effectiveness as a treatment. Relapses of human botulism after treatment have
been noted presumably due to the short half-life of BAT and poorer potency against
some BoNT subtypes (19). BAT requires slow intravenous (i.v.) infusion after dilution
into a total volume of 200 ml. This combined with hypersensitivity reactions makes it a
challenge to administer in mass casualty scenarios. As an alternative, we have been
developing serotype-specific monoclonal antibody combinations (three monoclonal
antibodies [MAbs]/serotype) that potently and neutralize BoNT by eliciting first-pass
clearance through the liver. Combining the three MAbs increases the potency
of BoNT/C neutralization by at least 3 orders of magnitude over that of individual
antibodies (C. Garcia-Rodriguez, unpublished data). In addition, we have reported the
generation of three-MAb combinations to BoNT/A (20–22), BoNT/B (23), BoNT/E (24),
BoNT/F (25), and BoNT/H (26) that are effective in mouse models of botulism and where
the three-MAb combinations are more potent than single MAbs by 2 to 3 orders of
magnitude. The products for botulism due to serotype A (NTM-1631, formerly XOMA
3AB) have completed a phase 1 clinical trial with no serious adverse effects (27). Phase
1 clinical trials for three-antibody combinations to treat botulism due to BoNT/B
(ClinicalTrials registration number NCT02779140) and BoNT/E (ClinicalTrials registration
number NCT03603665) are ongoing.
For the treatment and prevention of BoNT/C and BoNT/D botulism, we have
developed a four-MAb combination, NTM-1634, that consists of an equimolar cofor-
mulated mixture of four fully human IgG1 monoclonal antibodies (MAbs), all with the
same constant regions, referred to as XCD-a, XCD-b, XCD-c, and XCD-d. These MAbs
bind nonoverlapping epitopes on BoNT/C, BoNT/D, and their mosaic toxins with high
affinity and neutralize each of these BoNTs in the mouse neutralization assay. Here, we
report the results of a phase 1, single-center, placebo-controlled, double-blind, ran-
domized dose escalation study whose purpose was to evaluate the safety and phar-
macokinetics properties of NTM-1634.
RESULTS
Antibody characteristics. NTM-1634 consists of four human MAbs isolated from
yeast display libraries constructed from the antibody variable region genes of humans
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immunized with pentavalent botulinum toxoid (C. Garcia-Rodriquez et al, unpublished
data). Each MAb binds a nonoverlapping BoNT epitope with high affinity (Table 1).
Three of the MAbs bind all four BoNTs with an equilibrium dissociation constant (KD) of
109 M, while MAb XCD-b only binds BoNT/C and BoNT D/C. A combination of the
four parental MAbs from which MAbs XCD-a, XCD-b, XCD-c, and XCD-d were derived
had effective doses that protected 50% of mice (ED50s) challenged with 40,000 50%
lethal doses (LD50s) of BoNT/C of 5.0 g/mouse, of BoNT C/D of 7.5 g/mouse, and of
BoNT D/C of 7.5 g/mouse (C. Garcia-Rodriquez et al, unpublished data).
Subject demographic characteristics. The use of 24 research participants was
planned for these studies (Fig. 1). Twenty-five were enrolled, randomized, and included
in the study. Randomized participants were administered either the NTM-1634 or
placebo intravenously. No deaths or adverse events (AEs) leading to study discontin-
uation were reported. A summary of subject disposition is presented in Table 2. Two
subjects from cohort B (0.66 mg/kg) were lost to follow-up. One subject who received
placebo was lost to follow-up after day 2 and the other was lost to follow-up after day
57. The subject that was lost to follow-up after day 2 was replaced in cohort B at the
time of cohort C (Fig. 1). A total of 18 research participants, six per cohort, received
NTM-1634 (0.33 mg/kg, 0.66 mg/kg, or 1 mg/kg), and two research participants per
cohort, six in total, received placebo. The doses were chosen to (i) deliver a dose of
BoNT antitoxin that exceeded the current dose of BAT, (ii) achieve a serum concentra-
tion greater than the MAb KD for BoNT, and (iii) allow measurement of the concentra-
tion of each component MAb. For example, for a 70-kg subject, these doses would
provide a total neutralizing capacity of 1.85 108, 3.70 108, and 5.6 108 mouse
TABLE 1 Characteristics of the human monoclonal antibodies that comprise NTM-1634
Antibody
name
No. of amino
acids
Mol wt
(kDa)
KD (1012 M)
BoNT/C BoNT C/D BoNT D/C BoNT/D
XCD-a 1,332 145,899 1.10 2.43 15.34 16.93
XCD-b 1,338 146,476 35.79 NBa 0.80 NB
XCD-c 1,338 146,463 11.79 37.81 83.95 96.20
XCD-d 1,334 145,788 130.37 37.90 22.44 11.63
aNB, no detectable binding at a BoNT concentration of 1 M.
FIG 1 Consolidated Standards of Reporting Trials (CONSORT) diagram of clinical study design.
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LD50s of BoNT/C based on the preclinical data described above. This compares to a
single dose BoNT/C neutralizing capacity for BAT of 3.0 107 mouse LD50s.
The study participants ranged in age from 19 to 44 years. The majority of study
subjects were white (17 [68%]), of Hispanic or Latino background (13 [52%]), and female
(19 [74%]). The demographic characteristics were similar across the treatment groups
except cohort C, where all the participants who received active compound were female.
The demographic characteristics are summarized in Table 3.
Safety profile. No deaths or AEs leading to study discontinuation were reported.
Overall, two non-drug-related serious adverse events (SAEs) were reported. One subject
in cohort B (0.66 mg/kg) had an SAE of exacerbation of schizophrenia and one subject
in cohort C (1 mg/kg) had and SAE of wrist fracture. Treatment-emergent adverse
events (TEAEs) were reported in 19 of 25 subjects (76%), with a total of 69 TEAEs
reported over the course of the study (Table 4). Cohort A (0.33 mg/kg) had four of six
(66.7%) reporting 18 TEAEs. Cohort B (0.66 mg/kg) had five of six (83.3%) reporting 21
TEAEs. Cohort C (1 mg/kg) had six of six (100%) subjects reporting 20 TEAEs. The
placebo group had four of seven (57.1%) subjects reporting 10 TEAEs. The most
frequently reported TEAE was blood creatine phosphokinase increase, which occurred
in 5 (20%) of the subjects. The next most frequently reported TEAEs (reported in two
or more subjects overall) were hemoglobin decreases, hematuria, hematocrit decreases,
viral upper respiratory tract infection, white blood cell count decreases, blood calcium
decreases, blood potassium increases, blood sodium increases, cough, hypernatremia,
myalgia, neutrophil count decreases, and proteinuria. There were no clinically signifi-
cant abnormal electrocardiograms (ECGs) nor were there clinically meaningful trends
identified comparing baseline vital and ECG values to those at subsequent time points.
All TEAEs were considered by the investigator to be “not related” to the study drug.
Antidrug antibody (ADA) results were negative for all participants with the exception of
one subject who had a positive ADA result with a titer of 1.2 ng/ml for MAb XCD-b
TABLE 2 Summary of subject disposition (all subjects randomized)
Disposition
No. (%) treated with (mg/kg):
0.33 (n 6) 0.66 (n 6) 1 (n 6) Placebo (n 7) Total (n 25)
All subjects randomized 6 6 6 7 25
Subjects who were dosed (safety population) 6 (100) 6 (100) 6 (100) 7 (100) 25
Subjects who completed study 6 (100) 5 (83) 6 (100) 6 (85.7) 23 (92)
Subjects who discontinued early from study 0 1 (16.7) 0 1 (14.3) 2 (8)
Lost to follow-up 0 1 (16.7) 0 1 (14.3) 2 (8)
TABLE 3 Summary of subject demographics
Parameter
Value for group treated with (mg/kg):
0.33 (n 6) 0.66 (n 6) 1 (n 6) Placebo (n 7) Total (n 25)
Age (yr)
Mean 33.7 30.0 34.7 32.9 32.8
SD 7.53 7.95 9.29 6.82 7.59
Minimum 25 19 21 23 19
Maximum 42 42 44 40 44
Sex (n [%])
Male 2 (33.3) 2 (33.3) 0 2 (28.6) 6 (24.0)
Female 4 (66.7) 4 (66.7) 6 (100.0) 5 (71.4) 19 (76.0)
Ethnicity (n [%])
Hispanic or Latino 4 (66.7) 3 (50.0) 3 (50.0) 3 (42.9) 13 (52.0)
Not Hispanic or Latino 2 (33.3) 3 (50.0) 3 (50.0) 4 (57.1) 12 (48.0)
Race (n [%])
Black or African American 0 1 (16.7) 3 (50.0) 2 (28.6) 6 (24.0)
White 5 (83.3) 5 (83.3) 2 (33.3) 5 (71.4) 17 (68.0)
Other 1 (16.7) 0 1 (16.7) 0 2 (8.0)
Snow et al. Antimicrobial Agents and Chemotherapy
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predose on day 1. All postdose ADA results were negative for this participant. The
significance of this finding is unknown, but it may be due to the setting of the cut point
for ADA detection. The subject did not report any past medical history and experienced
no AEs during the study.
Pharmacokinetics analysis. A summary of the pharmacokinetics data is presented
in Table 5. Peak concentrations for each of the antibodies, regardless of dose, were
generally observed 1 to 2 h after the 1-h infusion. The peak concentrations of each of
the four antibodies were also similar. After the peak, the concentrations of all four
antibodies declined in a log-linear fashion, with a distinct distribution and terminal
elimination phase (Fig. 2). Serum concentrations for XCD-a were quantifiable up to day
TABLE 5 Summary of pharmacokinetics data
MAb
Cohort (dose
[mg/kg])
Cmax (ng/ml)/
GeoCV% Tmax (h [min, max])
AUC0–t (g·h/ml)/
GeoCV%
AUC0–∞ (g·h/ml)/
GeoCV%
t1/2 (days)/
GeoCV%
XCD-a A (0.33) 1,762/11.2 1.00 (1.00, 2.00) 207/16.4 2,745/8.8 10.9/11.4
B (0.66) 3,805/19.3 1.50 (1.00, 2.00) 525/28.1 635/11.1 10.6/17.5
C (1) 6,347/14.0 2.00 (1.00, 4.02) 961/14.3 1,001/14.2 10.2/9.3
XCD-b A (0.33) 1,969/10.7 2.00 (1.00, 2.08) 591/28.9 739/17.5 24.3/16.6
B (0.66) 4,296/21.3 1.00 (1.00, 2.00) 1,530/21.4 1,674/21.3 24/28.4
C (1) 7,226/10.2 2.00 (1.00, 4.00) 2,508/14.1 2,612/14.3 23.4/15.0
XCD-c A (0.33) 1,877/10.0 1.00 (1.00, 2.00) 542/22.6 624/22.3 20.2/18.1
B (0.66) 4,149/23.6 1.00 (1.00, 2.00) 1,339/23.8 1,492/20.7 22.3/27.5
C (1) 7,151/12.0 2.00 (1.00, 4.02) 2,193/15.9 2,281/16.3 21.4/14.9
XCD-d A (0.33) 1,830/14.0 2.00 (2.00, 4.00) 403/15.6 463/17.8 15.9/19.1
B (0.66) 4,080/17.7 1.00 (1.00, 4.00) 990/25.4 1,083/25.2 17.8/35.0
C (1) 6,829/10.5 1.00 (1.00, 4.00) 1,553/15.6 1,662/13.3 15.8/16.4
FIG 2 Serum concentration over time means from 6 subjects (error bars indicate standard deviations) at three dosing
levels: 0.33 mg/kg (blue), 0.66 mg/kg (red), and 1 mg/kg (green). Curves are least-square best fit; for all curves, R2  0.9.
Curves are least-squared fits and do not converge at zero antibody concentration in log scale as a result of the lower limit
of quantitation of the assay being 10 ng/ml and the lack of sampling after 150 days. (A) MAb XCD-a. (B) XCD-b. (C) XCD-c.
(D) XCD-d.
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29 in 5 of 6 subjects, day 43 in 3 of 6 subjects, and day 57 in 1 of 6 subjects who
received NTM-1634 0.33, 0.66, and 1 mg/kg, respectively. Serum concentrations of
XCD-b were quantifiable up to day 91 in 2 of 6 subjects, day 121 in 2 of 6 subjects, and
day 121 in 3 of 6 subjects who received NTM-1634 0.33, 0.66, and 1 mg/kg, respectively.
Serum concentrations of XCD-c were quantifiable up to day 91 in 1 of 6 subjects, day
121 in 1 of 6 subjects, and day 121 in 1 of 6 subjects who received NTM-1634 0.33, 0.66,
and 1 mg/kg, respectively. Serum concentrations of XCD-d were quantifiable up to day
57 in 2 of 6 subjects, day 91 in 2 of 6 subjects, and day 91 in 1 of 6 subjects who
received NTM-1634 0.33, 0.66, and 1 mg/kg, respectively.
The dose-adjusted maximum concentrations of drug in serum (Cmaxs) for all four
antibodies were similar across all three dose cohorts. In addition, the areas under the
concentration-time curves from 0 to infinity (AUC0–∞s) for XCD-b and XCD-c were not
different across all three dose cohorts, indicating dose proportionality over the 3-fold
dose range. The areas under the concentration-time curves from 0 to infinity (AUC0–∞s)
for XCD-a and XCD-d were lower than for XCD-b and XCD-c, with XCD-a having the
lowest AUC0–∞ across all three dose cohorts. Each of the four MAb had long half-lives
that varied from 10.2 to 24 days. XCD-b and XCD-c had longer half-lives (t1/2s) than
either XCD-a or XCD-d, with XCD-a having the shortest t1/2 at 263 h. The basis for the
differences in half-lives between MAbs is unclear, since the MAbs have similar pIs and
have the same antibody constant regions. The overall pharmacokinetics of each of the
four individual antibodies were roughly similar to each other, with the rank order of
XCD-b having the longest half-life and AUC followed by XCD-c, XCD-d, and then XCD-a.
DISCUSSION
BoNTs are classified by the Centers for Disease Control and Prevention (CDC) as one
of the highest-risk threat agents for bioterrorism due to their extreme potency and
lethality, ease of production and transport, and need for prolonged intensive care (3).
Thus, the development of countermeasures for all seven serotypes, including BoNT/C
and BoNT/D, is a high research priority. Both Iraq and the former Soviet Union produced
BoNT for use as weapons, and at least three additional countries (Iran, North Korea, and
Syria) have developed or are believed to be developing BoNT as instruments of mass
destruction (3, 28, 29). Iraq produced 19,000 liters of concentrated BoNT, more than any
other biothreat agent, of which 10,000 liters were weaponized in missile warheads or
bombs. The 19,000 liters represent an amount of toxin capable of killing the world’s
population three times over. The Japanese cult Aum Shinrikyo attempted to use BoNT
for bioterrorism by dispersing toxin aerosols at multiple sites in Tokyo (3).
Botulism causes significant morbidity and mortality, and exposure of even a small
number of civilians would paralyze the health care delivery system of any metropolitan
area. Treatment of botulism requires prolonged hospitalization in an intensive care unit
(ICU) and mechanical ventilation for up to 6 weeks. There are no current logistically
feasible prophylactic agents available in the United States as medical countermeasures.
Antitoxin is the only effective treatment for botulism and has been shown to reduce the
duration of hospitalization, duration of mechanical ventilation, and cost of hospitaliza-
tion (30). The current treatment for adult botulism is heptavalent (serotypes A to G)
equine botulism antitoxin (BAT) (18). BAT is immunogenic, and hypersensitivity reac-
tions have been reported, including serum sickness and asystole (18, 31).
As an alternative and potentially safer and more effective product, we have been
developing serotype-specific human or humanized MAb combinations that stoichio-
metrically neutralize BoNT by eliciting first-pass clearance through the liver (20, 27). In
addition, these antibodies are being used in diagnostic tests to identify the specific
serotype of botulinum neurotoxin that was causing the symptoms and provide guid-
ance for treatment (32, 33). This study was the first in-human assessment of NTM-1634,
a four-MAb combination which potently neutralizes BoNT/C, C/D, D/C, and D in rodents.
The results demonstrate that single escalating doses of NTM-1634 administered intra-
venously into healthy subjects were well tolerated and safe. In addition, these doses
also demonstrated acceptable immunogenicity profiles, with little ADA detected over
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the dose ranges and duration of the study. No dose-related SAEs were observed, and
the AEs that were observed between the three cohorts and placebo group were similar
in frequency, character, and severity. These results indicate that NTM-1634 may be a
safer product than the equine polyclonal antibody BAT (18).
Previous studies with NTM-1634 have demonstrated that the effectiveness of NTM-
1634 in neutralizing BoNT C/D is dependent on the presence of all four antibodies (C.
Garcia-Rodriquez et al, unpublished data). This is consistent with observations for other
anti-BoNT antibody combinations in development (20, 24, 25). It therefore follows that
the duration of effectiveness of the combination will be determined by the monoclonal
antibody that falls below the minimal effective levels most rapidly. The terminal t1/2s
were similar across the range of doses for each antibody. At all doses given, however,
XCD-a was cleared more rapidly than the other three, with XCD-d being the next most
rapidly cleared. However, all antibodies were detectable for a minimum of 4 weeks,
with the most rapidly clearing MAb, XCD-a, having a serum half-life of 11 days. This
contrasts with BAT, which is an F(ab=)2 product with short serum half-lives for BoNT/C
and BoNT/D (30 and 7.5 h, respectively). The long half-life of NTM-1634 may reduce the
likelihood of a relapse of botulism that has been reported with BAT (19).
While we have not directly compared the potency of NTM-1634 to BAT for BoNT/C
or BoNT/D, the potency of a BoNT/A MAb combination (NTM-1631) under development
is 400- to 600-fold more potent than BAT in mouse protection studies with BoNT/A1,
and a three-MAb combination to BoNT/F more than 150 to 450 times more potent than
BAT (25, 27) on a weight basis. The lowest dose of NTM-1634 studied (0.33 mg/kg)
would deliver a total BoNT/C neutralizing capacity of 1.85 108 mouse LD50s of
BoNT/C based on the preclinical data described above. This compares to a single dose
BoNT/C neutralizing capacity for BAT of 3.0 107 mouse LD50s, or more than 6-fold
more. This greater potency is expected, since polyclonal antisera rarely have more than
1% of the total IgG directed against the target antigen, compared to 100% for
recombinant IgG. The combined safety, potency, and long half-life of NTM-1634 make it
possible for potential intramuscular or subcutaneous administration after exposure and
prior to the development of symptoms, which is not possible with BAT. These features
would make NTM-1634 simpler to administer in a mass casualty scenario. The high potency
and long half-life would also permit administration of NTM-1634 for the prevention of
botulism as an alternative to vaccination. This is important, since there is no longer a
vaccine available to prevent types C and D botulism.
In summary, this study provides an early evaluation of the pharmacokinetics and
safety profile of NTM-1634. The highly potent protection in animal models and the
safety profile and long half-life of 1 month in humans demonstrate the potential
utility of NTM-1634 for treatment of botulism due to serotypes C and D. Thus, further
clinical development of NTM-1634 for the treatment and prevention of BoNT intoxica-
tion due to serotypes C and D is warranted.
MATERIALS AND METHODS
This was a phase 1, single-center, placebo-controlled, double-blind dose escalation study to evaluate
the safety, pharmacokinetics characteristics, and immunogenicity of NTM-1634 in healthy adults. This first
in-human study consisted of three cohorts (A, 0.33 mg/kg; B, 0.66 mg/kg; C, 1 mg/kg) of eight subjects
each. Each subject received a single i.v. infusion of NTM-1634 or placebo administered over 1 h. The
placebo was normal saline.
NTM-1634. NTM-1634 consists of four human single-chain Fv (scFv) MAbs isolated from yeast display
libraries constructed from the antibody variable region genes of humans immunized with pentavalent
botulinum toxoid (C. Garcia-Rodriquez et al, in preparation). The heavy- and light-chain variable region
genes of the scFv were inserted into vectors containing the human kappa and IgG1 constant region
genes to create human IgG1/kappa MAbs, and four separate stable CHO-K1 cell lines were established.
The IgG1 isotype was selected on the basis of studies showing the importance of Fc receptor engage-
ment for the synergy in potency seen when the MAbs are combined (J. D. Marks, unpublished data). Each
MAb (XCD-a, XCD-b, XCD-c, and XCD-d) was expressed and purified individually using protein A and
ion-exchange chromatography and then combined in equimolar amounts to create NTM-1634.
Subjects. The study enrolled a total of 25 healthy adult volunteers. Subjects in all cohorts partici-
pated in the study for approximately 21 weeks, including a 4-week screening period, a 3-day inpatient
stay, and approximately 17-week follow-up study after drug administration. Eligible research participants
were healthy male or healthy, nonpregnant, nonlactating females between the ages of 18 and 45 years.
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Subjects had body mass indices of between 18.5 and 30 kg/m2, negative illicit drug screens, and
adequate venous access for the infusion. Subjects were considered study ineligible if they had a history
of a chronic medical condition that would interfere with the accurate assessment of the objectives of the
study, a history of severe allergic reaction to any type of medications, bee stings, food, or environmental
factor or reaction to immunoglobulins, positive serology for HIV, HBsAg, or hepatitis C virus (HCV)
antibodies, were pregnant or breastfeeding, were previously exposed to BoNT and active drug, or have
alcohol dependence. Research subjects who had received any monoclonal antibody in the past or any
antibody or blood products, treatment with another investigational drug within 28 days of dosing,
donated blood within 56 days of enrollment, or use of H1 antihistamines or beta-blockers within 5 days
of dosing were also excluded. Additional exclusion criteria included a marked baseline prolongation of
QT/QTc interval, clinically significant electrocardiogram, systolic blood pressure of 140 mm Hg or
diastolic blood pressure 90 mm Hg, resting heart rate 50 or 100 beats per min, or oral temperature
of 38°C.
Study design. Subjects were randomized into three cohorts of eight subjects and admitted to the
study unit on day 1. Infusion occurred on day 1, and subjects remained at the clinic until discharge on
day 2 (25 h after the infusion had ended). Follow-up visits occurred on days 3, 4, 8, 15, 29, 43, 57, 91, and
121. Safety parameters included physical examination, 12-lead ECG, vital signs, and clinical laboratory
values. Pharmacokinetics samples were collected predose, at the end of infusion, 1, 3, 7, 23, 47, and 71 h
postinfusion, and on days 8, 15, 29, 43, 57, 91, and 121 for all cohorts. Dose escalation did not occur until
safety data from at least 7 subjects per cohort through day 8 were reviewed by the Safety Review
Committee comprising the principal investigator (D. M. Snow), Ology Bioservices Medical Representative
(C. N. Kraus), and the NIAID Division of Microbiology and Infectious Diseases Medical Monitor.
For each dosing cohort, the first two subjects were randomized 1:1 active/placebo so that one of the
first two subjects received active treatment and the other control. The treatment assignment of the
remaining six subjects in each cohort was 3:1 active/placebo. The randomization list was generated by
the unblinded study biostatistician and transferred to the unblinded study pharmacist prior to the start
of the study. The study staff participating in the administration of the study product and assessment of
subjects were not aware of the contents of the i.v. bag. Drug and placebo appeared identical.
The study drug was manufactured by XOMA Corporation (Berkeley, CA) and filled by Althea
Technologies (San Diego, CA). Assays developed for NTM-1643 characterization and release were
qualified using biological testing, including a MAb-specific enzyme-linked immunosorbent binding assay
(ELISA) which used recombinant BoNT/C protein domains (22, 34 and G. Manzanarez et al., unpublished
data), developed and qualified by Ology Bioservices, and an in vivo quadruple antibody protection assay
in mice, developed and qualified in collaboration with SRI International (Menlo Park, CA). The investi-
gational product was formulated as a 5-mg/ml, clear colorless, sterile aqueous solution in a pH 6.0
buffered vehicle without any preservatives. The drug product was supplied in 2-ml, pyrogen-free, type
1 glass vials. Placebo was a sterile, nonpyrogenic isotonic solution of 0.9% sodium chloride injection, USP
grade, and water for injection. The placebo did not contain preservatives, bacteriostatic or antimicrobial
agents, or added buffer. Normal saline was used to dilute the NTM-1634 for i.v. infusion and was supplied
in single-dose plastic containers.
Safety analyses. The safety endpoints were the occurrence of serious adverse events (SAEs)
following administration of NTM-1634 to the final follow-up visit, the occurrence of adverse events (AEs)
from administration of NTM-1634 to day 57, the occurrence of changes from baseline in physical
examination, vital signs, and clinical safety laboratory values following administration of NTM-1634 to the
final follow-up visit, and the occurrence of changes from baseline in ECG parameters after administration
of NTM-1634 on day 1 (day of infusion). Immunogenicity was assessed by determining the presence of
human anti-human antibodies.
Pharmacokinetics analyses. Four immunoassays were developed to measure the concentrations of
XCD-a, XCD-b, XCD-c, and XCD-d in serum samples. A bridging electrochemiluminescence (ECL) assay
was used (22, 27, 34). Biotinylated (b) and ruthenylated (ru) BoNT/C domains were used in the assay as
the capturing and detecting reagents, respectively. The assay uses the bivalent binding capability of the
antibodies to form a bridging complex with biotinylated-domain and ruthenylated-domain to generate ECL
signals for the measurement of the target antibody concentration in serum. Six assays were developed using
the same format for each antibody assay. ECL signals generated from captured immune complexes formed
when one arm of the MAb bound to a biotinylated domain and the other arm to the ruthenylated domain
were detected by a Meso-Scale Discovery (MSD)SECTOR Imager 6000 and reported in ECL units. Calibration
standards and quality control samples were prepared by spiking known amounts of each MAb into human
serum. With the minimum required dilution of 1:10, the lower limit of quantitation (LLOQ) was 10 ng/ml, with
a quantifiable range of 10 to 2,000 ng/ml.
Immunogenicity assays were developed and validated to detect anti-XCD-a, XCD-b, XCD-c, and
XCD-d antibodies in human serum. Bridging ECL assays used labeled MAbs for the capture and detection
of antidrug antibodies (ADAs) in serum. A mixture of biotinylated and ruthenylated XCD-a, XCD-b, XCD-c,
and XCD-d MAbs were incubated with human serum, and ECL signals were generated when one arm of
an ADA bound to a b-MAb and the other arm bound to a ru-MAb. Samples that generated a signal above
the screening cut point (SCP) were considered positive and confirmed with the use of a competitive assay
in which the serum samples were incubated with and without nonlabeled MAbs. Samples with ECL
signals above the confirmation cut point were considered positive and further analyzed for titers.
Statistical analyses. Pharmacokinetics (PK) parameters for each of the four monoclonal antibodies
of NTM-1634 (XCD-a, XCD-b, XCD-c, and XCD-d) were calculated from the serum concentration-time data
using noncompartmental techniques (Phoenix-WinNonlin version 6.3.0; Pharsight Corporation, St. Louis,
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MO) and actual sampling times based on the start of the infusion. The following PK parameters were
reported: area under the concentration time-curve (AUC) to the last concentration above the lower limit
of quantitation (AUC0–t), maximum observed concentration (Cmax), time that Cmax was observed (Tmax),
terminal elimination rate constant (z), AUC from time zero extrapolated to infinity (AUC0–∞), terminal
elimination half-life (t1/2), total clearance (CL), and volume of distribution (Vz). Summary of Tmax included
the number of non-missing observations (n), median, minimum, and maximum values only. For all other
PK parameters and concentrations, n, mean, standard deviation (SD), median, minimum, and maximum
values are presented. In addition, geometric mean (GeoMean) and geometric coefficient of variation
(GeoCV%) are presented for serum concentrations, Cmax, AUC0–t, AUC0–∞, t1/2, CL, and Vz.
The overall incidence of treatment-emergent AEs (TEAEs) (number and percentage of subjects) was
summarized by dose cohort, and overall for categories of degree of severity, SAEs, causally related TEAEs,
and SAEs by causality. The TEAEs were summarized and tabulated at both the subject (number
[percentage] of subjects) and event (number of events) level for each dose cohort and overall. Treatment-
emergent laboratory abnormalities by toxicity grades are summarized for each cohort and overall.
Observed values and change from baseline of continuous ECG measurements (heart rate, QRS duration
[milliseconds], PR interval [milliseconds], QT interval [milliseconds], and QTcF interval [milliseconds]) are
summarized by cohort and overall. The overall ECG interpretation is summarized as “normal,” “abnormal,
not clinically significant,” and “abnormal, clinically significant.”
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